Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383094 · ClinicalTrials.gov registry record · Phase 2
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
A Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Loren Mell, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 6
- Study locations
NCT03383094: Active Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Loren Mell, MD.
NCT03383094 is a Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Loren Mell, MD. The registered enrollment target is 126 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03383094, a Phase 2 study of Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Loren Mell, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
Primary Outcome
time from randomization to progression/relapse or death from any cause.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION Radiation therapy
Study Locations (6)
Arizona
- University of Arizona Cancer Center - Tucson
California
- UC San Diego Moores Cancer Center - La Jolla
Florida
- H. Lee Moffitt Cancer Center & Research Facility - Tampa
Missouri
- Washington University School of Medicine, Siteman Cancer Center - St Louis
Ohio
- University of Cincinnati Medical Center - Cincinnati
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03383094 still lists
NCT03383094 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower).
The record links to 10 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03383094 lists 6 locations in 6 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT03383094 about?
NCT03383094 is a clinical study titled "Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer". The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy (RT) in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT03383094?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2018-03-15. Estimated completion is 2027-12-31.
What conditions does trial NCT03383094 study?
This clinical trial studies the following conditions: Cancer, Head and Neck Squamous Cell Carcinoma, Tumor, Oral Cancer, Cancer Metastatic.
What interventions are being tested in trial NCT03383094?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03383094?
This trial is sponsored by Loren Mell, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03383094 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03383094's enrollment target sits among peer trials
126 282nd of 615 higher than 331 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI